Treatment discontinuation has become a central issue in studies with BCR-ABL tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). The oral session on clinical trials in CML featured two studies on treatment discontinuation: one assessing initial reduction before complete TKI withdrawal and a second study evaluating the impact of minimal residual disease (MRD) on the outcome of imatinib discontinuation. In addition to this, a study was presented with long-term data on 400mg imatinib as first-line treatment for CML together with a study assessing frontline bosutinib. Finally, a last abstract in this session evaluated the second-generation BCR-ABL TKI dasatinib in children and adolescents with CML.

(BELG J HEMATOL 2017;8(4):151–4)